Efficacy of liquid biopsy in colorectal cancer.
作者信息
Yan Masahiro, Funatsu Nozomi, Watanabe Megumu, Uetake Hiroyuki
机构信息
Department of Clinical Research, National Hospital Organization (NHO), Disaster Medical Center, Tokyo, Japan.
出版信息
J Gastrointest Oncol. 2025 Aug 30;16(4):1785-1788. doi: 10.21037/jgo-2025-268. Epub 2025 Aug 25.
Abstract
摘要
相似文献
1
Efficacy of liquid biopsy in colorectal cancer.液体活检在结直肠癌中的疗效。
J Gastrointest Oncol. 2025 Aug 30;16(4):1785-1788. doi: 10.21037/jgo-2025-268. Epub 2025 Aug 25.
2
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis.循环肿瘤DNA作为接受全身治疗的转移性结直肠癌患者的预后标志物：一项系统评价和荟萃分析。
Cancer Treat Rev. 2025 Sep;139:102999. doi: 10.1016/j.ctrv.2025.102999. Epub 2025 Jul 24.
3
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions.探索结直肠癌液体活检领域：当前见解与未来方向
Int J Mol Sci. 2025 Aug 6;26(15):7619. doi: 10.3390/ijms26157619.
4
Colorectal cancer: Application of selected liquid biopsy markers.结直肠癌：选定液体活检标志物的应用
Pol Przegl Chir. 2025 Mar 25;97(4):59-64. doi: 10.5604/01.3001.0055.0608.
5
ctDNA-guided adjuvant immunotherapy in colorectal cancer.ctDNA 引导的结直肠癌辅助免疫治疗
Immunotherapy. 2024;16(20-22):1197-1202. doi: 10.1080/1750743X.2024.2430941. Epub 2024 Nov 17.
6
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
7
Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization-Clinical Evidence and Challenges.
Diagn Cytopathol. 2025 Nov;53(11):580-591. doi: 10.1002/dc.70009. Epub 2025 Sep 4.
8
Prognostic and Predictive Value of Microsatellite Instability Analysis in Circulating Tumor DNA Using Digital Droplet PCR for Patients With Microsatellite Instability Colorectal Cancers.使用数字液滴PCR对微卫星不稳定型结直肠癌患者循环肿瘤DNA进行微卫星不稳定分析的预后和预测价值
Lab Invest. 2025 Apr 15;105(8):104176. doi: 10.1016/j.labinv.2025.104176.
9
Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.循环肿瘤 DNA 作为结直肠癌根治性切除术患者（接受或不接受辅助化疗）微小残留病评估和复发风险的标志物：一项系统评价和荟萃分析。
Int J Mol Sci. 2023 Jun 16;24(12):10230. doi: 10.3390/ijms241210230.
10
The utility of ctDNA in colorectal cancer with peritoneal metastases.循环肿瘤DNA（ctDNA）在伴有腹膜转移的结直肠癌中的应用
ANZ J Surg. 2023 Mar;93(3):506-509. doi: 10.1111/ans.18078. Epub 2022 Oct 6.
本文引用的文献
1
Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy.仅使用血浆检测循环肿瘤DNA可预测寡转移结直肠癌患者根治性治疗后的生存情况。
J Gastrointest Oncol. 2025 Apr 30;16(2):580-590. doi: 10.21037/jgo-24-819. Epub 2025 Apr 8.
2
The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen.日本结直肠癌辅助化疗的现状：从口服氟吡啶单药治疗到奥沙利铂方案的模式转变
Cancers (Basel). 2025 Feb 4;17(3):518. doi: 10.3390/cancers17030518.
3
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.基线 ctDNA 基因突变作为转移性结直肠癌使用帕尼单抗和化疗后生存的生物标志物。
Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12.
4
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.帕尼单抗联合贝伐珠单抗对比标准一线化疗方案联合贝伐珠单抗用于 RAS 野生型、左侧转移性结直肠癌患者的生存获益：一项随机临床试验。
JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428.
5
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.利用仅血浆循环肿瘤 DNA 检测在结直肠癌患者中检测微小残留病灶。
Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29.
6
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.I至III期结直肠癌患者血浆游离DNA的深度测序分析
JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528.
7
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.无细胞游离 DNA 在转移性结直肠癌中的应用：系统评价和荟萃分析。
Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4.
8
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.循环肿瘤DNA分析可检测II期结肠癌患者的微小残留病并预测复发。
Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.
9
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.循环 DNA 作为转移性结直肠癌患者管理护理的强有力的多标志物预后工具。
Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.
10
The consensus molecular subtypes of colorectal cancer.结直肠癌的共识分子亚型
Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.
Zotero 插件